Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Evaluation of Intravenous Talineuren in Parkinson's Disease
NCT04976127Phase 1Terminated
- Sponsor
- InnoMedica
- Start
- Dec 2021
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of talineuren in Parkinson's disease (PD) (3 arms), sponsored by InnoMedica. Primary endpoints: Occurrence of adverse events and Occurrence of serious adverse events. Started Dec 2021; status: terminated.
02
Drugs
talineuren
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04976127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04976127.